Literature DB >> 21637104

Why is genetic screening for autosomal dominant disorders underused in families? The case of hereditary hemorrhagic telangiectasia.

Barbara A Bernhardt1, Cara Zayac, Reed E Pyeritz.   

Abstract

PURPOSE: Appropriate management of autosomal dominant disorders reduces morbidity and mortality but relies on identifying which family members are affected. Genetic testing may identify relatives needing follow-up but is underused. We conducted this study to identify barriers to genetic testing for one disorder, hereditary hemorrhagic telangiectasia.
METHODS: Surveys and online discussion groups with people from hereditary hemorrhagic telangiectasia families.
RESULTS: Multiple barriers to hereditary hemorrhagic telangiectasia genetic testing were identified including lack of knowledge about genetic testing, problems with access, and emotional barriers. Many participants did not understand the rationale for hereditary hemorrhagic telangiectasia testing or benefits of early detection; believed that genetic testing is expensive and not covered by insurance; and believed that primary care providers do not know how to order genetic testing. Access to hereditary hemorrhagic telangiectasia testing is limited by distance from a hereditary hemorrhagic telangiectasia center or a genetics clinic. Emotional barriers include fear of insurance discrimination; denial of having hereditary hemorrhagic telangiectasia or being at risk; and guilt and stigma.
CONCLUSION: Voluntary disease organizations should develop and disseminate brief educational materials that describe the rationale for genetic testing and emphasize the benefits of early detection and treatment. In addition, laboratories offering genetic testing should provide support for primary care physicians to order and interpret genetic tests.

Entities:  

Mesh:

Year:  2011        PMID: 21637104      PMCID: PMC3166421          DOI: 10.1097/GIM.0b013e31821d2e6d

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  53 in total

1.  Participation by clinical geneticists in genetic advocacy groups.

Authors:  Angela E Lin; Sharon F Terry; Barbara Lerner; Rebecca Anderson; Mira Irons
Journal:  Am J Med Genet A       Date:  2003-05-15       Impact factor: 2.802

Review 2.  Barriers to the provision of genetic services by primary care physicians: a systematic review of the literature.

Authors:  Sandy Suther; Patricia Goodson
Journal:  Genet Med       Date:  2003 Mar-Apr       Impact factor: 8.822

3.  The patient with hypertrophic cardiomyopathy has a family.

Authors:  Imke Christiaans; Arthur A M Wilde
Journal:  Heart       Date:  2011-02       Impact factor: 5.994

4.  Facilitating family communication about predictive genetic testing: probands' perceptions.

Authors:  Clara L Gaff; Veronica Collins; Tiffany Symes; Jane Halliday
Journal:  J Genet Couns       Date:  2005-04       Impact factor: 2.537

5.  Genetic counseling and testing in families with hereditary nonpolyposis colorectal cancer.

Authors:  Donald W Hadley; Jean Jenkins; Eileen Dimond; Kenneth Nakahara; Liam Grogan; David J Liewehr; Seth M Steinberg; Ilan Kirsch
Journal:  Arch Intern Med       Date:  2003-03-10

6.  Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians.

Authors:  Alexandra E Shields; David Blumenthal; Kevin B Weiss; Catherine B Comstock; Douglas Currivan; Caryn Lerman
Journal:  J Gen Intern Med       Date:  2005-02       Impact factor: 5.128

7.  Impact of self-reported familiarity with guidelines for cystic fibrosis carrier screening.

Authors:  Maria A Morgan; Deborah A Driscoll; Stanley Zinberg; Jay Schulkin; Michael T Mennuti
Journal:  Obstet Gynecol       Date:  2005-06       Impact factor: 7.661

8.  Characteristics of health information gatherers, disseminators, and blockers within families at risk of hereditary cancer: implications for family health communication interventions.

Authors:  Laura M Koehly; June A Peters; Regina Kenen; Lindsey M Hoskins; Anne L Ersig; Natalia R Kuhn; Jennifer T Loud; Mark H Greene
Journal:  Am J Public Health       Date:  2009-10-15       Impact factor: 9.308

Review 9.  Delivery of genomic medicine for common chronic adult diseases: a systematic review.

Authors:  Maren T Scheuner; Pauline Sieverding; Paul G Shekelle
Journal:  JAMA       Date:  2008-03-19       Impact factor: 56.272

10.  Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations.

Authors:  Esme Finlay; Jill E Stopfer; Eric Burlingame; Katherine Goldfeder Evans; Katherine L Nathanson; Barbara L Weber; Katrina Armstrong; Timothy R Rebbeck; Susan M Domchek
Journal:  Genet Test       Date:  2008-03
View more
  14 in total

Review 1.  Global trends on fears and concerns of genetic discrimination: a systematic literature review.

Authors:  Annet Wauters; Ine Van Hoyweghen
Journal:  J Hum Genet       Date:  2016-01-07       Impact factor: 3.172

Review 2.  Personal utility in genomic testing: a systematic literature review.

Authors:  Jennefer N Kohler; Erin Turbitt; Barbara B Biesecker
Journal:  Eur J Hum Genet       Date:  2017-03-15       Impact factor: 4.246

3.  Consumer attitudes towards the establishment of a national Australian familial cancer research database by the Inherited Cancer Connect (ICCon) Partnership.

Authors:  Laura Forrest; Gillian Mitchell; Letitia Thrupp; Lara Petelin; Kate Richardson; Lyon Mascarenhas; Mary-Anne Young
Journal:  J Community Genet       Date:  2017-08-18

4.  Physicians' perspectives on the uncertainties and implications of chromosomal microarray testing of children and families.

Authors:  M Reiff; K Ross; S Mulchandani; K J Propert; R E Pyeritz; N B Spinner; B A Bernhardt
Journal:  Clin Genet       Date:  2012-09-18       Impact factor: 4.438

5.  Public awareness of genetic nondiscrimination laws in four states and perceived importance of life insurance protections.

Authors:  Alicia A Parkman; Joan Foland; Beth Anderson; Debra Duquette; Holly Sobotka; Mary Lynn; Shelley Nottingham; William David Dotson; Katherine Kolor; Summer L Cox
Journal:  J Genet Couns       Date:  2014-09-23       Impact factor: 2.537

6.  Access to personalized medicine: factors influencing the use and value of gene expression profiling in breast cancer treatment.

Authors:  Y Bombard; L Rozmovits; M Trudeau; N B Leighl; K Deal; D A Marshall
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

7.  Life experiences of individuals with hereditary hemorrhagic telangiectasia and disclosing outside the family: a qualitative analysis.

Authors:  Leigh Ann Higa; Jamie McDonald; Deborah O Himes; Erin Rothwell
Journal:  J Community Genet       Date:  2015-09-04

8.  A long diagnostic delay in patients with Hereditary Haemorrhagic Telangiectasia: a questionnaire-based retrospective study.

Authors:  Paola Pierucci; Gennaro M Lenato; Patrizia Suppressa; Patrizia Lastella; Vincenzo Triggiani; Raffaella Valerio; Mario Comelli; Daniela Salvante; Alessandro Stella; Nicoletta Resta; Giancarlo Logroscino; Francesco Resta; Carlo Sabbà
Journal:  Orphanet J Rare Dis       Date:  2012-06-07       Impact factor: 4.123

Review 9.  A systematic review of geographical inequities for accessing clinical genomic and genetic services for non-cancer related rare disease.

Authors:  Stephanie Best; Nada Vidic; Kim An; Felicity Collins; Susan M White
Journal:  Eur J Hum Genet       Date:  2022-01-20       Impact factor: 5.351

10.  The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia.

Authors:  Scott D Grosse; Sheree L Boulet; Althea M Grant; Mary M Hulihan; Marie E Faughnan
Journal:  Genet Med       Date:  2013-05-23       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.